L. Casei DG® in Patients With Irritable Bowel Syndrome.

NACompletedINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

November 6, 2017

Primary Completion Date

May 4, 2021

Study Completion Date

December 30, 2021

Conditions
IBS - Irritable Bowel Syndrome
Interventions
DIETARY_SUPPLEMENT

L.casei DG

"(At least 24 billion live cells per capsule)~1 capsule, b.i.d. for 12 weeks"

DIETARY_SUPPLEMENT

PLACEBO

1 capsule, b.i.d. for 12 weeks

Trial Locations (20)

40100

Azienda Ospedaliero-Universitaria S. Orsola Malpighi, Bologna

80100

Policlinico, Napoli

Unknown

A.O. Bolognini, Seriate

"A.O. G. Brotzu- Ospedale San Michele", Cagliari

AOU di Cagliari - Policlinico di Monserrato, Cagliari

Ospedale Valduce, Como

ASST-FTB-Sacco, Milan

Policlinico San Donato, San Donato Milanese

Ospedale Sant'Andrea, Vercelli

Gastroenterologia Universitaria Policlinico Giovanni XXIII, Bari

Azienda ULSS 1, Belluno

Ospedale SS. Annunziata, Chieti

Fondazione IRCCS Policlinico, Milan

Policlinico Federico II, Napoli

Azienda Ospedaliera di Padova, Padua

Fondazione IRCCS Policlinico S. Matteo, Pavia

U.O. Gastroenterologia Universitaria, Pisa

A.O. San Camillo-Forlanini, Roma

Ospedale Sant'Andrea, Roma

00128

Policlinico Universitario Campus Biomedico, Roma

All Listed Sponsors
collaborator

1Med

OTHER

lead

SOFAR S.p.A.

INDUSTRY

NCT03449628 - L. Casei DG® in Patients With Irritable Bowel Syndrome. | Biotech Hunter | Biotech Hunter